🍎 🍕 Less apples, more pizza 🤔 Have you seen Buffett’s portfolio recently?Explore for Free

Analysis-U.S. Senate Democrats' bill will make mark on climate, healthcare costs

Published 08/06/2022, 07:42 PM
Updated 08/06/2022, 09:08 PM
© Reuters. FILE PHOTO: U.S. Senate Majority Leader Chuck Schumer (D-NY) departs after a news conference to tout the $430 billion drug pricing, energy and tax bill championed by Democrats at the U.S. Capitol in Washington, U.S. August 5, 2022.  REUTERS/Jonathan Ernst
NG
-

By David Morgan

WASHINGTON (Reuters) - The $430 billion climate change, healthcare and tax bill the U.S. Senate began debating on Saturday night could deliver a major win for Democrats and could help reduce the carbon emissions that drive climate change while also cutting costs for the elderly.

Democrats hope the bill, which they aim to push through the Senate over united Republican opposition, will boost their chances in the Nov. 8 midterm elections, when Republicans are favored to recapture the majority in at least one chamber of Congress.

The package, called the Inflation Reduction Act, is a dramatically scaled-back version of a prior bill backed by Democratic President Joe Biden that was blocked by maverick Senate Democrats Joe Manchin and Kyrsten Sinema as too expensive.

"It's what the American people want," Senate Majority Leader Chuck Schumer told reporters. "We're prioritizing the middle class, working families, those struggling to get to the middle class, instead of what Republicans do: prioritize those at the very top."

If the Senate passes the bill, which likely would require a tie-breaking vote from Vice President Kamala Harris, it would send the legislation on to the Democratic-controlled House of Representatives, which intends to take it up on Friday, after which Biden could sign it into law.

Republicans blasted the bill as a spending "wish list" that they argued would hurt an economy weighed down by inflation, saying it would kill jobs, raise energy costs and undermine growth at a time when the economy is facing a potential recession.

"The Democrats’ most recent reckless tax and spending spree suffers from a serious case of policy whiplash," said Republican Senator Chuck Grassley on Saturday. "The last thing businesses and families need right now are tax hikes and a rash of poorly vetted policies creating even more confusion and uncertainty in the economy."

About half of Americans -- some 49% -- support the bill, including 69% of Democrats and 34% of Republicans, according to a Reuters/Ipsos poll conducted Aug. 3 and 4. The most popular element of the bill is giving Medicare the power to negotiate drug prices, which 71% of respondents support, including 68% of Republicans.

Economists, who say the legislation could help the Federal Reserve combat inflation, do not expect a sizeable impact on the economy in coming months.

CLIMATE FOCUS

With $370 billion in climate-focused spending, it would become the most consequential climate change bill ever passed by Congress.

The bill offers businesses and families billions in incentives to encourage purchases of electric vehicles and energy-efficient appliances, as well as to spur new investments in wind and solar power that would double the amount of new, clean electricity-generating capacity coming online in the United States by 2024, according to modeling by the Repeat Project at Princeton University.

That would help put the U.S. on course to meet its pledge to slash its greenhouse gas emissions in half by 2030 below 2005 levels, made at last year's Glasgow climate summit.

While environmental groups largely embraced the bill, they noted that compromises secured by Manchin, who represents coal-producing West Virginia, would prolong U.S. use of fossil fuels.

Those provisions include rules that would only allow the federal government to authorize new wind and solar energy developments on federal land when it is also auctioning rights to drill for oil and natural gas.

DRUG COSTS

The legislation would lower drug costs for the government, employers and patients, said Juliette Cubanski, deputy director of the Medicare program at the Kaiser Family Foundation.

    "Perhaps the biggest effect would be for people with prescription drug coverage through Medicare," she said.

    A key change is the provision allowing the federal Medicare health plan for older and disabled Americans to negotiate lower prescription drug prices.

    The pharmaceutical industry says price negotiation would stifle innovation. Negotiated prices for 10 of the costliest drugs for Medicare would apply starting in 2026, with that number rising until it caps at 20 a year in 2029.

    The nonpartisan Congressional Budget Office estimates Medicare would save $101.8 billion over 10 years by negotiating drug prices.

    The provision also introduces a $2,000 annual cap on out-of-pocket costs for the elderly through the Medicare program.

TAX PROVISIONS

The bill also imposes a new excise tax on stock buybacks, a late change after Sinema raised objections over another provision that would have imposed new levies on carried interest, currently a tax loophole for hedge fund and private equity financiers. The provision was dropped.

The excise tax is expected to raise an additional $70 billion in tax revenue per year, lawmakers said. That is more than the carried interest provision had been forecast to raise.

© Reuters. FILE PHOTO: U.S. Senate Majority Leader Chuck Schumer (D-NY) departs after a news conference to tout the $430 billion drug pricing, energy and tax bill championed by Democrats at the U.S. Capitol in Washington, U.S. August 5, 2022.  REUTERS/Jonathan Ernst/File Photo

A report by the nonpartisan Congressional Budget Office released prior to that last change estimated the measure would reduce the federal deficit by a net $101.5 billion over the next decade.

That was about one-third of the $300 billion in deficit reduction predicted by Senate Democrats, but excluded a projected $204 billion revenue gain from increased Internal Revenue Service enforcement.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.